01
Cash & equivalents increased 36.1%
Cash & equivalents changed +36.1% from the comparable as-filed period.
$39.8M→$54.1MComparable → current
· Pharmaceutical Preparations
RESEARCH SNAPSHOTMBX Biosciences, Inc.'s latest supported as-filed period reports net income of -$37.1M, 91.1% below the comparable as-filed period. Every value below links to its SEC accession and metric lineage.
The most important deterministic changes, ranked by magnitude, issuer history, persistence, and accounting profile.
Cash & equivalents changed +36.1% from the comparable as-filed period.
Net income changed -91.1% from the comparable as-filed period.
Operating income changed -87.7% from the comparable as-filed period.
Research & development changed +74.8% from the comparable as-filed period.
Each point keeps the date investors could first observe it and its accession.
MBX · as filed with the SEC · reported-date aware
Direct SEC links, filing dates, report periods, and amendment flags.
0001193125-26-336849SEC ↗8-KAug 6, 2026Period Aug 6, 20260001193125-26-336841SEC ↗4Aug 5, 2026Period Aug 4, 20260001193125-26-335373SEC ↗4Aug 4, 2026Period Aug 3, 20260001193125-26-331642SEC ↗4Aug 4, 2026Period Aug 3, 20260001193125-26-331639SEC ↗8-KJul 13, 2026Period Jul 9, 20260001193125-26-302098SEC ↗8-KJun 12, 2026Period Jun 12, 20260001193125-26-268477SEC ↗Transaction semantics distinguish purchases, sales, awards, exercises, withholding, and derivatives.
| Filed / transacted | Reporting owner | Semantics | Shares | Price | Notional | Source |
|---|---|---|---|---|---|---|
| Aug 4, 2026Filed Aug 5, 2026 | Azoulay SalomonChief Medical Officer | Open Market SaleDirect | 370 | $66 | $24,335 | Form 4 ↗ |
GrossPattern stores immutable raw artifacts, accession-scoped facts, parser and metric versions, dependency edges, quality state, and channel-specific publication rights. A restricted or unknown ancestor blocks the page and API automatically.
SEC source policy ↗Method note “Materiality” here is an analytical magnitude band, not a legal conclusion. Full filing-text semantic changes remain unpublished while excerpt rights and review thresholds are unresolved.
Latest supported period in this snapshot: 2026-06-30. Duration facts use direct quarterly or annual SEC contexts; GrossPattern does not manufacture missing Q4 values.
0001193125-26-259236